Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0004-282x2008000300025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intraoperative Molecular Imaging With Pafolacianine: Histologic Characteristics of Identified Nodules.
Clin Lung Cancer
November 2024
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH. Electronic address:
Background: With increased early detection efforts, surgery for early-stage lung cancer is expected to rise. Pafolacianine is the first FDA approved targeted optical imaging agent indicated as an adjunct for intraoperative identification of malignant and nonmalignant pulmonary lesions in adult patients with known or suspected cancer in the lung.
Methods: This is a retrospective review of the malignant and nonmalignant lesions identified by pafolacianine with intraoperative molecular imaging (IMI) in the multi-center Phase 2 and Phase 3 ELUCIDATE clinical trials.
The Clinical Outcomes of Cervical Spine Chordoma: A Nationwide Multicenter Retrospective Study.
Neurospine
September 2024
Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Article Synopsis
- The study focuses on chordoma, a rare and aggressive tumor of the cervical spine, highlighting its resistance to standard treatments and the necessity of surgical intervention.
- Conducted across 7 medical centers, the research analyzes data from 45 patients over a median of 52 months, tracking local recurrence and survival outcomes.
- Results show that while age significantly influences mortality rates, the method of tumor removal and additional treatments do not have a considerable impact on controlling the disease or improving survival rates.
Conventional Spinal Chordomas: Investigation of SMARCB1/INI1 Protein Expression, Genetic Alterations in Gene, and Clinicopathological Features in 89 Patients.
Cancers (Basel)
August 2024
Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
Article Synopsis
- Recent studies show a partial loss of SMARCB1/INI1 expression in skull base chordomas, suggesting potential treatment options for these tumors; this study focused on 89 patients with spinal chordomas.
- The analysis found that 41.6% of patients exhibited partial SMARCB1/INI1 loss, primarily due to a deletion on chromosome 22, with significant implications for tumor location and surgical outcomes.
- Key findings indicated that tumor location (specifically in the sacrococcygeal region) and adequate surgical margins were linked to better disease-free survival rates, highlighting important factors for patient prognosis.
Unusual Presentation of Thoracic Chordoma with Spinal Epidural Hematoma: A Rare Case Report and PRISMA-Driven Systematic Review.
Clin Med Insights Case Rep
July 2024
Department of Neurosurgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
A chordoma is a slow growing, locally invasive, low-grade tumor belonging to the sarcoma family. It mainly affects the sacrum and skull base. We present a case of thoracic chordoma initially presented with epidural hematoma (EDH), which is a rare clinical entity.
View Article and Find Full Text PDFSurgical and Oncologic Outcome following Sacrectomy for Primary Malignant Bone Tumors and Locally Recurrent Rectal Cancer.
Cancers (Basel)
June 2024
University Center for Orthopedics, Trauma Surgery and Plastic Surgery, Sarcoma Center at the National Center for Tumor Diseases (NCT/UCC), University Hospital Carl Gustav Carus Dresden, 01307 Dresden, Germany.
Introduction: Bone sarcoma or direct pelvic carcinoma invasion of the sacrum represent indications for partial or total sacrectomy. The aim was to describe the oncosurgical management and complication profile and to analyze our own outcome results following sacrectomy.
Methods: In a retrospective analysis, 27 patients (n = 8/10/9 sarcoma/chordoma/locally recurrent rectal cancer (LRRC)) were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!